Related Experiment Videos
The incurable wound revisited: progress in human rabies prevention?
C A Hanlon1, M Niezgoda, P A Morrill
1Rabies Section MS-G33, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Vaccine
|March 21, 2001
Summary
Rabies immune globulins (RIGs) are crucial for postexposure prophylaxis but are not widely available. This study evaluated RIGs and monoclonal antibodies (Mabs) in a hamster model, suggesting Mabs as a promising alternative for rabies prevention.
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- Rabies is a critical global viral zoonosis.
- Current postexposure prophylaxis relies on vaccines and rabies immune globulins (RIGs).
- RIGs face challenges in availability and affordability, necessitating alternative solutions.
Purpose of the Study:
- To compare the efficacy of human and equine RIGs, with or without vaccine, against rabies.
- To evaluate a neutralizing murine monoclonal antibody (Mab) as a potential alternative to RIGs.
- To assess the utility of animal models for predicting human postexposure prophylaxis efficacy.
Main Methods:
- Utilized a Syrian hamster model to test postexposure efficacy of RIGs and a Mab.
- Administered RIGs (alone or with vaccine) and a single neutralizing Mab.
- Evaluated product effectiveness and clearance rates in the animal model.
Main Results:
- Animal models are effective surrogates for evaluating rabies postexposure prophylaxis.
- Significant variations in experimental effectiveness and clearance were observed among different RIG preparations.
- A neutralizing Mab demonstrated potential efficacy in the postexposure setting.
Conclusions:
- Monoclonal antibodies (Mabs) present a viable alternative to rabies immune globulins (RIGs).
- Further research into Mabs is warranted for improved human rabies prevention strategies.
- The study highlights the importance of accessible and affordable rabies prophylaxis options.